CD274 and head and neck squamous cell carcinoma: In HNSCC, PD-L1 has become a key therapeutic target, with many HPV-negative patients overexpressing PD-1 as high as 46%–87%.8‐10 However, when anti-PD-L1 checkpoint inhibitors have been used in clinical testing, suboptimal response rates have been observed.